Results from Long-term Combination Therapy Statins with Fenofibrate in Patients with Mixed Hyperlipidemia

Abstract

Data from patients with mixed dyslipidemia and a high risk of cardiovascular disease (CVD) were included in the multicenter retrospective study. The purpose was to analyze the efficacy and safety of lipidlowering therapy with micronized fenofibrate (Tricor®) in combination with rosuvastatin in patients from Moscow and Moscow region. The analysis included data from outpatient monitoring of 150 patients with mixed hyperlipidemia and triglyceride (TG) levels >272.3 mmol/l. 12 months of combination lipid-lowering therapy resulted in a decrease from baseline TG and low-density lipoprotein cholesterol (LDL-C)
plasma levels by 34.8% and 47.9% from baseline, respectively. The percentages of patients with TG levels ≤2.3 mmol/l and ≤1.7 mmol/l were 96.7% and 60.3%, respectively. No cases of therapy discontinuation due to adverse events were reported. In general, combination therapy with rosuvastatin and fenofibrate was characterized by efficacy, good tolerability and adherence.